See the DrugPatentWatch profile for stiripentol

Stiripentol is primarily used in the early stages of Dravet syndrome, specifically during the seizure-prone childhood phase, unlike fenfluramine which is used in later stages. Dravet syndrome is a rare and severe form of epilepsy that begins in the first year of life [1].

Stiripentol is an anticonvulsant medication that is used as an add-on therapy for the treatment of Dravet syndrome in conjunction with clobazam. It is approved for use in children and adults, but it is most commonly used in children between the ages of 2 and 5 years old, during the peak period of seizure activity [2].

On the other hand, fenfluramine is a medication that was originally developed as an appetite suppressant, but it has been found to have potential therapeutic benefits in the treatment of Dravet syndrome. Fenfluramine has been shown to reduce the frequency and severity of seizures in patients with Dravet syndrome, but it is typically used in later stages of the disease, after other treatments have been tried [3].

It is important to note that both stiripentol and fenfluramine have potential side effects and risks, and they should only be used under the close supervision of a healthcare provider. Patients and caregivers should be aware of the potential risks and benefits of these medications and should work closely with their healthcare provider to determine the most appropriate treatment plan for their individual needs [4].

In summary, stiripentol is primarily used in the early stages of Dravet syndrome, while fenfluramine is typically used in later stages. Both medications have potential benefits and risks, and they should only be used under the close supervision of a healthcare provider.

Sources:

1. Dravet Syndrome Foundation. (2021). What is Dravet Syndrome? <https://www.dravetfoundation.org/what-is-dravet-syndrome/>
2. National Organization for Rare Disorders. (2021). Stiripentol. <https://rarediseases.org/rare-disease/dravet-syndrome/#stiripentol>
3. ClinicalTrials.gov. (2021). Fenfluramine in Dravet Syndrome. <https://clinicaltrials.gov/ct2/show/NCT03639931>
4. DrugPatentWatch.com. (2021). Stiripentol. <https://www.drugpatentwatch.com/drugs/stiripentol>